Carbonic anhydrase inhibitor (systemic IOP and ICP reduction)
Pregnancy: Avoid in first trimester (teratogenic in animals). Use only if essential.
Acetazolamide
Brand names: Diamox
Adult dose
Dose: Acute glaucoma: 500 mg IV or 500 mg oral stat; IIH: 250–1000 mg/day in divided doses
Route: IV (acute); oral (maintenance)
Frequency: Acute: single dose; Maintenance: 2–4 times daily
Max: 1 g IV (acute angle-closure); 3 g/day (IIH specialist doses)
Acute angle-closure glaucoma: 500 mg IV (over 5 min) as emergency; then 250 mg oral QDS. Idiopathic intracranial hypertension (IIH): start 250 mg BD, increase by 250 mg/week to max 2–3 g/day. Altitude sickness prevention: 250 mg BD, start 24h before ascent.
Paediatric dose
Dose: 8 mg/kg
Route: Oral or IV
Frequency: Every 6–8 hours
Max: 750 mg/day
8 mg/kg/day in divided doses every 6–8 hours (max 750 mg/day). IIH in adolescents: 25 mg/kg/day in divided doses (specialist). Weight loss and dietary management essential in paediatric IIH.
Dose adjustments
Renal
Avoid if eGFR <30 (risk of renal stones and metabolic acidosis).
Hepatic
Avoid in severe hepatic impairment.
Paediatric weight-based calculator
8 mg/kg/day in divided doses every 6–8 hours (max 750 mg/day). IIH in adolescents: 25 mg/kg/day in divided doses (specialist). Weight loss and dietary management essential in paediatric IIH.
Clinical pearls
- Acute angle-closure: emergency — combine with pilocarpine 2%, IV acetazolamide, and arrange urgent ophthalmology
- Paraesthesia (tingling in extremities) is expected side effect — not allergic — counsel patient
- Carbonated drinks unpalatable (carbonic anhydrase in taste buds) — warn patient
- Potassium supplement often needed with prolonged use (renal K+ loss)
- IIH: weight loss is first-line intervention; acetazolamide adjunct
Contraindications
- Severe renal impairment
- Severe hepatic impairment
- Sulfonamide hypersensitivity
- Addison's disease
- Hypokalaemia, hyponatraemia
Side effects
- Hypokalaemia and metabolic acidosis
- Paraesthesia (tingling in fingers/toes — common, usually benign)
- Renal calculi
- GI upset and anorexia
- Drowsiness
- Dysgeusia (carbonated drinks taste flat)
- Stevens-Johnson syndrome (rare)
Interactions
- Salicylates — increased acetazolamide toxicity
- Lithium — increased urinary excretion (reduced lithium levels)
- Antiepileptics — increased risk of metabolic acidosis
- Potassium-depleting diuretics — additive hypokalaemia
Monitoring
- U&E and bicarbonate
- Renal function
- IOP (ophthalmology)
- Serum potassium
Reference: BNFc; BNF; NICE CG102 Glaucoma; IIH UK guidelines; BNFc. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- IABP Timing Assessment · Mechanical Circulatory Support
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- SIRS Criteria and Sepsis Definition · Sepsis
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
Pathways
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme